参考文献：
[1]. Janku F, YapT A, Meric-Bernstam F. Targeting the PI3K pathway in cancer: are we makingheadway?[J]. Nature Reviews Clinical Oncology, 2018, 15(5): 273.
[2]. Cancer GenomeAtlas Network. Comprehensive molecular portraits of human breast tumours[J].Nature, 2012, 490(7418): 61.
[3]. André F,Ciruelos E, Rubovszky G, et al. Alpelisib for PIK3CA-mutated, hormonereceptor–positive advanced breast cancer[J]. New England Journal of Medicine,2019, 380(20): 1929-1940.
[4]. André F,Ciruelos E M, Juric D, et al. LBA18 Overall survival (os) results from SOLAR-1,a phase III study of alpelisib (ALP) + fulvestrant (FUL) for hormonereceptor-positive (HR+), human epidermal growth factor receptor 2-negative(HER2-) advanced breast cancer (ABC)[J]. Annals of Oncology, 2020, 31(S4): S1150-S1151.
[5]. Rugo H S,Lerebours F, Ciruelos E, et al. Alpelisib (ALP) + fulvestrant (FUL) in patients(pts) with PIK3CA-mutated (mut) hormone receptor-positive (HR+), humanepidermal growth factor receptor 2-negative (HER2–) advanced breast cancer(ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDKi) +aromatase inhibitor (AI): BYLieve study results[J]. Journal of ClinicalOncology, 2020, 38(15_suppl): 1006.
[6]. PD2-07. Alpelisib+ letrozole in patients with PIK3CA-mutated, hormone-receptor positive (HR+),human epidermal growth factor receptor-2-negative (HER2-) advanced breastcancer (ABC) previously treated with a cyclin-dependent kinase 4/6 inhibitor(CDK4/6i) + fulvestrant: BYLieve study results. 2020 SABCS.
[7]. Jones R H,Casbard A, Carucci M, et al. Fulvestrant plus capivasertib versus placebo afterrelapse or progression on an aromatase inhibitor in metastatic, oestrogenreceptor-positive breast cancer (FAKTION): a multicentre, randomised,controlled, phase 2 trial[J]. The Lancet Oncology, 2020, 21(3): 345-357.
[8]. Schmid P,Abraham J, Chan S, et al. Capivasertib Plus Paclitaxel Versus Placebo PlusPaclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer:The PAKT Trial[J]. Journal of Clinical Oncology, 2019, 38(5): 423-433.
[9]. Dent R,Oliveira M, Isakoff S J, et al. 139O Final results of the double-blind placebo(PBO)-controlled randomised phase II LOTUS trial of first-line ipatasertib(IPAT) + paclitaxel (PAC) for inoperable locally advanced/metastatictriple-negative breast cancer (mTNBC) [J]. Annals of Oncology, 2020, 31(S4): S64-S65.
[10]. Wander S A,Juric D, Supko J G, et al. Phase Ib trial to evaluate safety and anti-tumoractivity of the AKT inhibitor, ipatasertib, in combination with endocrinetherapy and a CDK4/6 inhibitor for patients with hormone receptor positive(HR+)/HER2 negative metastatic breast cancer (MBC) (TAKTIC)[J]. Journal ofClinical Oncology, 2020, 38(15_suppl): 1066.
[11]. Royce M,Bachelot T, Villanueva C, et al. Everolimus Plus Endocrine Therapy forPostmenopausal Women With Estrogen Receptor–Positive, Human Epidermal GrowthFactor Receptor 2–Negative Advanced Breast Cancer: A Clinical Trial[J]. JAMA Oncology,2018, 4(7): 977-984.
[12]. Piccart M,Hortobagyi G N, Campone M, et al. Everolimus plus exemestane forhormone-receptor-positive, human epidermal growth factor receptor-2-negativeadvanced breast cancer: overall survival results from BOLERO-2[J]. Annals of Oncology,2014, 25(12): 2357-2362.
[13]. PD1-01. Open-label,randomized, phase 2 study of sapanisertib (TAK-228/MLN0128) in combination withfulvestrant in postmenopausal women with estrogen receptor-positive (ER+)/humanepidermal growth factor receptor-2-negative (HER2-) advanced or metastaticbreast cancer (MBC) that previously progressed during or after aromataseinhibitor therapy. 2020 SABCS.
[14]. Nunnery S E,Mayer I A. Targeting the PI3K/AKT/mTOR Pathway in Hormone-Positive BreastCancer[J]. Drugs, 2020: 1685-1697.
top1
top2
top3
top4
top5
top6
X